New Alzheimer's drug aims to ease symptoms and help caregivers
NCT ID NCT07633470
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety and tolerability of the drug Zunveyl in 150 adults aged 50 and older with mild to moderate Alzheimer's disease. Over 12 weeks, researchers will monitor side effects and whether the drug helps reduce neuropsychiatric symptoms like agitation or mood changes, and lessens distress for caregivers. The goal is to see if Zunveyl can improve daily life for patients and their families.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tekton Research Saint Louis Psychiatry
RECRUITINGSt Louis, Missouri, 63128, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••